Khanna Sahil, Pardi Darrell S
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Therap Adv Gastroenterol. 2014 Mar;7(2):72-86. doi: 10.1177/1756283X13508519.
Clostridium difficile was first described as a cause of diarrhea in 1978 and in the last three decades has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. There also has been a rise in severe outcomes from C. difficile infection (CDI). There have been tremendous advancements in the field of CDI with the identification of newer risk factors, recognition of CDI in populations previously thought not at risk and development of better diagnostic modalities. Several treatment options are available for CDI apart from metronidazole and vancomycin, and include new drugs such as fidaxomicin and other options such as fecal microbiota transplantation. This review discusses the epidemiology, risk factors and outcomes from CDI, and focuses primarily on existing and evolving treatment modalities.
艰难梭菌于1978年首次被描述为腹泻的病因,在过去三十年中已呈流行状态,在医疗保健机构和社区环境中的发病率和严重程度均不断增加。艰难梭菌感染(CDI)导致的严重后果也有所增加。随着新的危险因素被识别、先前认为无风险人群中CDI得到认识以及更好的诊断方法的开发,CDI领域取得了巨大进展。除甲硝唑和万古霉素外,CDI还有几种治疗选择,包括新型药物如非达霉素以及其他选择如粪便微生物群移植。本综述讨论了CDI的流行病学、危险因素和后果,并主要关注现有的和不断发展的治疗方式。